

Research team reports that AAV1.NT-3 gene therapy prevents age-related sarcopenia

March 15 2023



NT-3 gene transfer improves myelin thickness of peripheral nerves and neuromuscular junction assembly in C57BL/6 mice. Credit: *Aging* (2023). DOI: 10.18632/aging.204577



A new research paper titled "AAV1.NT-3 gene therapy prevents agerelated sarcopenia" has been published in *Aging*.

Sarcopenia is progressive loss of <u>muscle</u> mass and strength occurring during normal aging with significant consequences on the quality of life for elderly. Neurotrophin 3 (NT-3) is an important autocrine factor supporting Schwann cell survival and differentiation and stimulating axon regeneration and myelination. NT-3 is involved in the maintenance of neuromuscular junction (NMJ) integrity, restoration of impaired radial growth of muscle fibers through activation of the Akt/mTOR pathway.

In this new study, researchers Burcak Ozes, Lingying Tong, Morgan Myers, Kyle Moss, Alicia Ridgley, and Zarife Sahenk from Nationwide Children's Hospital and The Ohio State University used a triple muscle-specific creatine kinase (tMCK) promoter to restrict NT-3 expression to the <u>skeletal muscle</u> and self-complimentary adeno-associated virus serotype 1 (scAAV1) as vector to assess the therapeutic efficacy of AAV1.NT-3 in wild type-aged C57BL/6J mice, a model for natural aging and sarcopenia.

"Quantitative histopathologic parameters served to address age-related changes in muscle, peripheral nerve and NMJ," the researchers write.

The treatment efficacy was assessed at 6 months post-injection using runto-exhaustion and rotarod tests, in vivo muscle contractility assay, and histopathological studies of the peripheral nervous system, including NMJ connectivity and muscle. AAV1.NT-3 gene therapy in WT-aged C57BL/6 mice resulted in functional and in vivo muscle physiology improvements, supported by quantitative histology from muscle, peripheral nerves and NMJ.



Hindlimb and forelimb muscles in the untreated cohort showed the presence of a muscle- and sex-dependent remodeling and fiber size decrease with aging, which was normalized toward values obtained from 10 months old WT mice with treatment. The <u>molecular studies</u> assessing the NT-3 effect on the oxidative state of distal hindlimb muscles, accompanied by western blot analyses for mTORC1 activation were in accordance with the histological findings.

"When considering the burden of sarcopenia on the lifestyle of elderly, and on the healthcare system, we believe this preclinical study is providing strong support for AAV.NT-3 gene therapy in the successful management of <u>sarcopenia</u>, as a serious and plausible option in the future," the researchers note.

More information: Burcak Ozes et al, AAV1.NT-3 gene therapy prevents age-related sarcopenia, *Aging* (2023). DOI: 10.18632/aging.204577

Provided by Impact Journals

Citation: Research team reports that AAV1.NT-3 gene therapy prevents age-related sarcopenia (2023, March 15) retrieved 23 May 2024 from <u>https://medicalxpress.com/news/2023-03-team-aav1nt-gene-therapy-age-related.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.